Selective and noncovalent targeting of RAS mutants for inhibition and degradation

Activating mutants of RAS are commonly found in human cancers, but to date selective targeting of RAS in the clinic has been limited to KRAS(G12C) through covalent inhibitors. Here, we report a monobody, termed 12VC1, that recognizes the active state of both KRAS(G12V) and KRAS(G12C) up to 400-times...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nat Commun
Main Authors: Teng, Kai Wen, Tsai, Steven T., Hattori, Takamitsu, Fedele, Carmine, Koide, Akiko, Yang, Chao, Hou, Xuben, Zhang, Yingkai, Neel, Benjamin G., O’Bryan, John P., Koide, Shohei
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8113534/
https://ncbi.nlm.nih.gov/pubmed/33976200
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-021-22969-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados